Spots Global Cancer Trial Database for clofarabine
Every month we try and update this database with for clofarabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00577694 | Leukemia | clofarabine gemtuzumab ozog... | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes | NCT01302106 | Myelodysplastic... | Clofarabine plu... | 55 Years - 80 Years | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma | NCT00338494 | B-Cell Lymphoma | Clofarabine | 18 Years - | Yale University | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia | NCT01196013 | Acute Lymphobla... | Clofarabine | 1 Year - 21 Years | Sanofi | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | NCT00703820 | Acute Myeloid L... | Cytarabine Daunorubicin Etoposide Clofarabine CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia | NCT01132573 | Acute Leukemias... Philadelphia Ch... Recurrent Adult... Untreated Adult... | entinostat clofarabine pharmacological... laboratory biom... | 21 Years - | National Cancer Institute (NCI) | |
| Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | NCT02349178 | Leukemia, Acute... Acute Myeloid L... | Clofarabine Cyclophosphamid... Etoposide | - 39 Years | Medical College of Wisconsin | |
| Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia | NCT02544789 | Acute Lymphobla... | Clofarabine | 1 Year - 21 Years | Betta Pharmaceuticals Co., Ltd. | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Clofarabine Bone Marrow Cytoreduction | NCT00724009 | Leukemia | Clofarabine | 18 Years - | University of Chicago | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | NCT01700946 | Recurrent B-Cel... Recurrent Child... | dexamethasone vincristine sul... rituximab clofarabine cyclophosphamid... etoposide aldesleukin pegaspargase methotrexate mercaptopurine cytarabine mitoxantrone teniposide vinblastine natural killer ... laboratory biom... therapeutic hyd... allogeneic hema... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML | NCT02686593 | Acute Myeloid L... | Clofarabine, Ar... | 18 Years - 65 Years | The University of Hong Kong | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Stem Cell Transplant for CLL | NCT01629511 | Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom... | Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | NCT02883049 | B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk... | Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | NCT01160354 | Acute Myelogeno... | Plerixafor Clofarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) | NCT00156013 | Lymphoma, B-Cel... Lymphoma, Non-H... | CLOFARABINE | 18 Years - | Oncology Specialists, S.C. | |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | NCT00334074 | Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Clofarabine and... | 18 Years - 85 Years | Baylor Research Institute | |
| Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01252667 | Acute Myeloid L... | Allogeneic Hema... Clofarabine Cyclosporine Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... | 2 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | NCT00299156 | Myelodysplastic... Chronic Myelomo... | Clofarabine | - | M.D. Anderson Cancer Center | |
| Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma | NCT00691652 | Lymphoma | rituximab clofarabine DNA methylation... gene expression... microarray anal... polymerase chai... high performanc... laboratory biom... | 18 Years - 89 Years | OHSU Knight Cancer Institute | |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | NCT01119066 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Multiple Myelom... | total body irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine Clofarabine (CliniMACS) T-c... | - 69 Years | Memorial Sloan Kettering Cancer Center | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | NCT02883049 | B Acute Lymphob... B Acute Lymphob... Central Nervous... Testicular Leuk... | Clofarabine Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Etoposide Hydrocortisone ... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | NCT03136146 | Recurrent Acute... Recurrent Adult... Recurrent Burki... Recurrent Burki... Recurrent Child... Recurrent High ... Refractory Acut... Refractory Burk... Refractory Burk... Refractory High... Refractory Lymp... | Bortezomib Clofarabine Cyclophosphamid... Dexamethasone Etoposide Ofatumumab Pegfilgrastim Rituximab Vincristine Sul... | 15 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00983528 | Acute Lymphobla... | Alemtuzumab Clofarabine | 16 Years - | University of California, San Diego | |
| Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | NCT00593645 | Myelodysplastic... Acute Myeloid L... | Clofarabine Cytarabine Thymoglobulin Stem cell infus... | 18 Years - | Washington University School of Medicine | |
| Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | NCT01193400 | Acute Myelogeno... | Clofarabine Cytarabine | 60 Years - | PETHEMA Foundation | |
| A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) | NCT01090167 | Acute Myelogeno... | clofarabine | 20 Years - 74 Years | Sanofi | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Clofarabine in High Risk Myelodysplastic Syndrome (MDS) | NCT01063257 | Myelodysplastic... | Clofarabine | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT | NCT05917405 | Acute Myeloid L... | Fludarabine Busulfan ATG Clofarabine | 18 Years - 99 Years | Nantes University Hospital | |
| A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) | NCT00373529 | Acute Myelogeno... Acute Myeloid L... | clofarabine | 60 Years - | Sanofi | |
| Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia | NCT00838240 | Leukemia Myelodysplastic... | clofarabine cytarabine idarubicin | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS | NCT01423175 | Acute Myeloid L... MDS | Clofarabine, ar... FLAMSA | 18 Years - | Hannover Medical School | |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | NCT01885689 | Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related... | clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological... | 18 Years - 75 Years | City of Hope Medical Center | |
| Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | NCT00088218 | Acute Myeloid L... Myelodysplastic... | Clofarabine Ara-C | 60 Years - | M.D. Anderson Cancer Center | |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT04994808 | Acute Myeloid L... Myelodysplastic... | Clofarabine Fludarabine Hematopoietic C... Total-Body Irra... Treosulfan | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | NCT00924443 | Acute Myeloid L... | clofarabine | 65 Years - | Sanofi | |
| Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia | NCT00081887 | Chronic Lymphoc... Leukemia | Clofarabine | - | M.D. Anderson Cancer Center | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00814164 | Leukemia | clofarabine daunorubicin hy... cytogenetic ana... protein express... immunologic tec... pharmacological... | 60 Years - 120 Years | Roswell Park Cancer Institute | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02085408 | Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult... | Daunorubicin Cytarabine Clofarabine Decitabine Observation Allogeneic hema... | 60 Years - | Eastern Cooperative Oncology Group | |
| A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | NCT00531232 | Myelodysplastic... Secondary Acute... | Clofarabine | 18 Years - | Sanofi | |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) | NCT01160354 | Acute Myelogeno... | Plerixafor Clofarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | NCT00943592 | Advanced Hemato... Leukemia Preleukemia | Clofarabine Melphalan Campath Stem Cell Trans... | 18 Years - 75 Years | University of Chicago | |
| Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients | NCT01003678 | Myelodysplastic... | Clofarabine | 18 Years - | Roswell Park Cancer Institute | |
| A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma | NCT00201669 | Non-Hodgkin's L... | Clofarabine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | NCT01794702 | Leukemia | Decitabine Idarubicin Cytarabine Clofarabine | 18 Years - 64 Years | M.D. Anderson Cancer Center | |
| Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | NCT00708721 | Cancer Chronic Myelomo... | Clofarabine | 18 Years - | University of Utah | |
| Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes | NCT01302106 | Myelodysplastic... | Clofarabine plu... | 55 Years - 80 Years | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | NCT00081822 | Acute Myeloid L... | clofarabine Ara-C | 60 Years - | University of Alabama at Birmingham | |
| Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL | NCT00477945 | Non Hodgkin's L... | clofarabine | 18 Years - 70 Years | Indiana University | |
| Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) | NCT00903760 | Myelodysplastic... | Decitabine Clofarabine | 18 Years - | M.D. Anderson Cancer Center | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01252667 | Acute Myeloid L... | Allogeneic Hema... Clofarabine Cyclosporine Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... | 2 Years - | Fred Hutchinson Cancer Center | |
| Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | NCT01960387 | Acute Myeloid L... | Clofarabine Cytarabine | 18 Years - | University of Pittsburgh | |
| Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias | NCT00882076 | Leukemia | Clofarabine Mitoxantrone Etoposide | 18 Years - 70 Years | Milton S. Hershey Medical Center | |
| Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | NCT01158885 | Minimal Residua... Leukemia, Lymph... Leukemia, Myelo... | Clofarabine Cytarabine intr... Methotrexate Intrathecal (IT... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia | NCT00838240 | Leukemia Myelodysplastic... | clofarabine cytarabine idarubicin | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | NCT00697671 | Acute Lymphobla... Chronic Myeloge... Juvenile Myelom... Myelodysplastic... Non-Hodgkin's L... | NK Cell Infusio... Immunotherapy Miltenyi Biotec... Interleukin-2 (... Clofarabine Cyclophosphamid... Etoposide | - 18 Years | St. Jude Children's Research Hospital | |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | NCT03096782 | Accelerated Pha... Acute Biphenoty... Acute Leukemia Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chemotherapy-Re... Chronic Lymphoc... Chronic Myeloge... Chronic Myelomo... Hodgkin Lymphom... Langerhans Cell... Minimal Residua... Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Recurrent Hodgk... Refractory Acut... Refractory Myel... Small Lymphocyt... Therapy-Related... | Anti-Thymocyte ... Busulfan Clofarabine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | NCT01025154 | Acute Myeloid L... | Clofarabine Idarubicin Cytarabine | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Allogeneic Stem Cell Transplant for CLL | NCT01629511 | Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom... | Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | NCT01960387 | Acute Myeloid L... | Clofarabine Cytarabine | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
